Glycemic control has been tested against placebo in randomized MSC trials.
Metabolic health is where regenerative medicine meets hard numbers. Glycated hemoglobin, insulin requirements, and insulin sensitivity are all measurable, which means the cell therapy research here can be judged on data rather than testimonials.
This page covers what randomized trials report, what they explicitly did not find, and why your baseline labs decide whether any of it is relevant to you.
Aurenza does not claim that regenerative medicine treats, cures, or reverses diabetes or any metabolic condition.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
What the Research Shows
Metabolic health is where regenerative medicine meets the hardest numbers in this field, because glycated hemoglobin and insulin requirements are lab values, not impressions. The trials here were run against placebo, blinded, and published.
The anchor is a single-center, double-blinded, randomized, placebo-controlled phase II trial in Stem Cell Research and Therapy (2022): 91 adults with type 2 diabetes received three intravenous infusions of umbilical cord MSCs or placebo and were followed 48 weeks. At the finish line, 20% of the treated group reached the primary endpoint of HbA1c under 7% together with at least a 50% cut in daily insulin, versus 4.55% on placebo. HbA1c fell 1.31 points against 0.63, and glucose infusion rate, a direct measure of insulin sensitivity, improved significantly only in the treated group, with no major treatment-related adverse events. The full open-access results are registered under NCT02302599, and a continuous glucose monitoring analysis of the same program found significantly more treated patients reached time-in-range of 70% or better with HbA1c under 7% at both 9 and 48 weeks.
The pooled literature points the same way: a 2021 meta-analysis in Stem Cell Research and Therapy covering 239 participants found HbA1c significantly lower after MSC treatment, with a mean difference of 1.51 points, alongside reduced insulin requirements, and a 2025 meta-analysis restricted to randomized controlled trials pooled the RCT base across both diabetes types at 12 months. Even in recent-onset type 1 diabetes, a phase I/II randomised double-blind placebo-controlled trial in Diabetologia (2023) found umbilical cord MSC treatment preserved endogenous insulin production.
The Honest Line
The same phase II trial that produced those numbers found no improvement in islet beta-cell function: the effect pattern pointed to insulin sensitivity, not to the pancreas producing more insulin, which directly contradicts the way this therapy is often sold as regrowing the pancreas. A 2024 pooled analysis likewise notes that in some programs early gains were not sustained over time, and durability beyond roughly a year remains an open question. No study shows a guarantee it works every time, or that it will work for you, and every trial studied cells as an addition to standard care, never a replacement for your endocrinologist's plan.
Why This Is Exactly Where a Candidacy Review Comes In
Type 2 diabetes runs from newly diagnosed and diet-controlled to long-standing disease with complications, and the trials enrolled defined groups at defined stages. Your labs decide where you sit relative to those patients, which is why the process starts by measuring them. Every trial above produced its results in selected patients who met specific criteria. That is the gap between "documented in research" and "right for you," and it is the gap a candidacy review exists to close. Before anything is recommended, your bloodwork, biomarkers, imaging, and history are reviewed by a physician panel to establish whether you are actually in the population the research describes. If the picture supports moving forward, you will know exactly why. If it does not, you will be told that, plainly. That is where to start.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
What Your Candidacy Review Covers
- Your current glycemic picture, including HbA1c trend, medications, and insulin use.
- Complication status, since kidney, eye, nerve, and vascular involvement each change the calculus.
- Your metabolic and inflammatory biomarkers, which define your baseline and what a meaningful change would look like.
- Your full medication list and treating physician's plan, which any discussion must fit inside rather than replace.
- Physician panel review, with endocrine input where the case calls for it.
What to Ask Any Provider
Which randomized trials are you relying on, and does my disease stage match their patients? Are you proposing this alongside my current treatment or instead of it? What is being administered, at what verified cell count, by what route? How will we measure whether anything changed, on which labs, at which intervals? What would make me a poor candidate?
The Honest Limits
Individual results cannot be predicted or guaranteed. These applications are not FDA approved for diabetes or metabolic conditions, and the procedure takes place in Mexico under COFEPRIS regulation. Never adjust insulin or other diabetes medication except under the direction of your treating physician.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
Free consultation with a care consultant, many of whom are registered nurses. No sales reps. No receptionist.